Two fourtreatment crossover studies were performed using 12 adult male volunteers in each with seven different commercially available prednisolone tablets. Plasma samples were assayed for prednisolone by a radioimmunoassay method. Statisacal analyses of the data, by analysis of variance for crossover design (ANOVA), showed no significant differences among the treatment averages at any of the sampling times except at 0.25 and 4 hr in one of the studies. There were also no significant differences among the treatment averages for peak plasma level, time of peak plasma level, area 0–12 hr, area 0–24 hr, and the halflife of elimination of prednisolone. We conclude that the average plasma concentrations of prednisolone are superimposable in a sta...
The purposes of this study were: (1) to determine under steady-state conditions whether the renal cl...
In this pre-formulation study, the effect of individual factors influencing the penetration rate of ...
Literature data relevant to the decision to allow a waiver of in vivo bioequivalence (BE) testing fo...
Two four-treatment crossover bioavailability studies were performed in panels of 12 adult male volun...
The in vitro dissolution rates of prednisolone from five commercially available 5- mg prednisolone t...
The average time to reach half-maximal plasma concentration of prednisolone and the average plasma c...
Two four-treatment crossover bioavailability studies were performed in panels of 12 adult male volun...
The aim of the study was to assess the pharmacokinetic and bioavailability of 2 formulations of 5-mg...
To assess the bioavailability of a oral prednisolone preparation, prednisolone crossover pharmacoki...
Literature data relevant to the decision to allow a waiver of in vivo bioequivalence (BE) testing fo...
Introduction: Prednisolone is a class II substance according to the Biopharmaceutics Classification ...
Introduction: Prednisolone is a class II substance according to the Biopharmaceutics Classification ...
Prednisone and prednisolone bioavailability in renal transplant patients. Prednisone and prednisolon...
Solid dosage forms for oral use, particularly tablets, are the most highly used dosage forms in ther...
Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/117227/1/cpt1979262232.pd
The purposes of this study were: (1) to determine under steady-state conditions whether the renal cl...
In this pre-formulation study, the effect of individual factors influencing the penetration rate of ...
Literature data relevant to the decision to allow a waiver of in vivo bioequivalence (BE) testing fo...
Two four-treatment crossover bioavailability studies were performed in panels of 12 adult male volun...
The in vitro dissolution rates of prednisolone from five commercially available 5- mg prednisolone t...
The average time to reach half-maximal plasma concentration of prednisolone and the average plasma c...
Two four-treatment crossover bioavailability studies were performed in panels of 12 adult male volun...
The aim of the study was to assess the pharmacokinetic and bioavailability of 2 formulations of 5-mg...
To assess the bioavailability of a oral prednisolone preparation, prednisolone crossover pharmacoki...
Literature data relevant to the decision to allow a waiver of in vivo bioequivalence (BE) testing fo...
Introduction: Prednisolone is a class II substance according to the Biopharmaceutics Classification ...
Introduction: Prednisolone is a class II substance according to the Biopharmaceutics Classification ...
Prednisone and prednisolone bioavailability in renal transplant patients. Prednisone and prednisolon...
Solid dosage forms for oral use, particularly tablets, are the most highly used dosage forms in ther...
Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/117227/1/cpt1979262232.pd
The purposes of this study were: (1) to determine under steady-state conditions whether the renal cl...
In this pre-formulation study, the effect of individual factors influencing the penetration rate of ...
Literature data relevant to the decision to allow a waiver of in vivo bioequivalence (BE) testing fo...